Navigation Links
U.S. FDA Grants Priority Review to the New Drug Application for Bayer's Regorafenib to Treat Patients with Metastatic Colorectal Cancer
Date:6/28/2012

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., June 28, 2012 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ:  ONXX) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA will complete its review within six months from the receipt of the NDA submission, rather than the standard 10-month review cycle. 

The submission was based upon data from the pivotal, global Phase III CORRECT study.

About Regorafenib
Regorafenib is an investigational oral multi-kinase inhibitor and is currently being investigated in clinical trials for its potential to treat patients with various tumor types.

Regorafenib is an investigational agent and is not approved by the FDA, EMA or other health authorities. 

Regorafenib is one of several cancer compounds in Bayer's development pipeline. In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, Inc., under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology. Bayer and Onyx will co-promote regorafenib in the U.S.

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty phar
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
2. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
3. Schulman Associates IRB offers oncology-focused review board
4. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
5. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
6. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
7. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
8. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
9. New Wireless Keyboard Rechargeable, Washable for Healthcare Applications
10. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
11. New, Affordable Flow Cytometer Cell Sorter Expands Access to Wider Range of Life Science Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... -- Statistics released from a number of organizations show ... the holidays, beginning with Thanksgiving eve, which is now ... The data, highlighted in an Infographic released ... their annual Sober Days for the Holidays public ... and increased rates of DUI injuries and deaths during ...
(Date:11/22/2014)... Research and Markets  has announced the addition ... 2014-2017" report to their offering. ... protein drug market has been expanding rapidly owing to ... like. During 2005-2013, sales of recombinant protein drugs available ... 19.1%, and it is projected that ...
(Date:11/21/2014)... 21, 2014  The University of Maryland,s A. James ... groundbreaking of the new A. James Clark Hall at ... will cultivate transformative new engineering and biomedical technologies to ... at 10:00 a.m. on November 21 at the site ... Lot, adjacent to the Jeong H. Kim Engineering Building, ...
Breaking Medicine Technology:Alarming Stats Show Holiday Drinking an Issue for Many 2China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... is natural that all customers using the services of online ... for them and getting their order within the shortest possible ... and well-taken. This site assures new and regular clients with ... security. It uses the most updated methods to make every ...
... HeartWare International, Inc. (Nasdaq: HTWR ) (ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the Canaccord ... 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time). ...
Cached Medicine Technology:A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to International Clients 2HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2
(Date:11/23/2014)... (PRWEB) November 24, 2014 For the ... and retailer, has launched a great promotion for many ... ). Customers can get the best choice with amazing ... shopping at Tidebuy.com. , It is easy to ... now. Besides that, this selection is also famous for ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank company, ... 8 year warranty on its selected hot water tanks. As ... to the impending winter season, it was important for Pro ... that the company provides. As a result, Pro Ace will ... Bradford hot water tanks. , “Every installer who works ...
(Date:11/23/2014)... 2014 (HealthDay News) -- The holidays can be a ... overload can trigger major meltdowns, an expert says. ... of circumstances, but when you have children with special ... occupational therapy professor at University of the Sciences in ... best to let your hosts or visitors know what ...
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
(Date:11/23/2014)... November 23, 2014 AngelWeddingDress.com ... a new selection of beach wedding dresses. “If you ... prices, visit AngelWeddingDress.com as soon as possible. Here you ... The sales manager says. , Holding a big marriage ... And choosing a beautiful beach wedding dress is uppermost ...
Breaking Medicine News(10 mins):Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2
... Reveal Deficiencies in Care for Individuals across the Country , ... Members who recently sought expert medical consultations from Best ... course of treatment, according to data released today. , ... clinical reviews of cases of Best Doctors members. Best Doctors ...
... Need to Reduce Disparities in Meningococcal Vaccination; Increase Educational ... Md., Dec. 2 The National Foundation ... Outreach. Protect.) Meningitis! coalition, composed of many ... issued a Call to Action to improve adolescent meningococcal ...
... workers, people affected by jet leg , , TUESDAY, Dec. 2 ... insomnia caused by jet lag or night shifts, according to ... II study included 39 people randomly assigned to receive either ... tasimelteon, or a placebo. They were monitored for seven nights ...
... a prototype blood scanner that can find cancer markers ... potentially allowing for earlier treatment and dramatically improved chances ... chips can find cancer-associated proteins in a blood serum ... greater sensitivity than existing commercial devices. In fact, the ...
... new naming structure, Kessler Foundation continues to improve the ... , WEST ORANGE, N.J.Dec. 2 ... disabilities, Henry H. Kessler Foundation, announced today the organization,s ... changing the names of its two main divisions to ...
... , , NEW YORK, Dec. ... JNPC; "Juniper") Sorpresa! , America,s fastest-growing Spanish-language ... Juega Como un MLS Pro , the climax of the ... 7th at 7 PM EST. , , ...
Cached Medicine News:Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:Drug Effective for Temporary Sleep Disruptions 2Health News:Stanford blood scanner detects even faint indicators of cancer 2Health News:Stanford blood scanner detects even faint indicators of cancer 3Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3Health News:Sorpresa! Premieres Juega Como un MLS Pro 2
... offers accuracy, speed, ease of use, ... is an Auto Refractor/Keratometer with both ... elevation, automatic alignment, focusing, printing, high-speed ... other features that have made the ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone ophthalmic suspension is a sterile antimicrobial and anti-inflammatory suspension for ophthalmic use....
Fluorometholone ophthalmic suspension USP, 0.1% is a topical anti-inflammatory agent for ophthalmic use....
... tool that allows to see the fundus ... stimulated. Besides it also includes the refractive ... between the pupil picture and the fundus ... is especially suited for animal research and ...
Medicine Products: